Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
Our results demonstrated the potential of Chi to overcome IM resistance in vitro and in vivo. By inhibiting the Warburg effect through the PPARγ/mTOR/PKM2 pathway, Chi resensitizes CML cells towards imatinib treatment. Combining IM with Chi is an alternative therapeutic option for CML management, especially for IM-resistant CML patients.
Authors
- Bing Xu (ORCID: https://orcid.org/0009-0006-6893-5226)
- Weihang Shan
- Zhijuan Lin (ORCID: https://orcid.org/0000-0001-8077-3932)
- Yuelong Jiang
- Manman Deng (ORCID: https://orcid.org/0000-0003-2819-6685)
- Qian Lai (ORCID: https://orcid.org/0000-0002-4282-7757)
- Liuzhen Yang
- Jie Zha (ORCID: https://orcid.org/0000-0002-3995-0340)
- Mengya Zhong
- Jingwei Yao
- Hongpeng Duan
- Li Zhang (ORCID: https://orcid.org/0000-0002-6774-2733)
Institutions
- Xiamen University (CN)
- First Affiliated Hospital of Xiamen University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s40164-024-00589-1
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Xiamen Municipal Bureau of Science and Technology
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province